Cargando…

Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib

BACKGROUND: Thymidine kinase 1 (TK1) is a cell cycle-regulated enzyme with peak expression in the S phase during DNA synthesis, and it is an attractive biomarker of cell proliferation. Serum TK1 activity has demonstrated prognostic value in patients with early-stage breast cancer. Because cyclin-dep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bagegni, Nusayba, Thomas, Shana, Liu, Ning, Luo, Jingqin, Hoog, Jeremy, Northfelt, Donald W., Goetz, Matthew P., Forero, Andres, Bergqvist, Mattias, Karen, Jakob, Neumüller, Magnus, Suh, Edward M., Guo, Zhanfang, Vij, Kiran, Sanati, Souzan, Ellis, Matthew, Ma, Cynthia X.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5699111/ https://www.ncbi.nlm.nih.gov/pubmed/29162134 http://dx.doi.org/10.1186/s13058-017-0913-7

Ejemplares similares

A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN)
por: Ademuyiwa, Foluso O., et al.
Publicado: (2023)

Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy
por: Cabel, Luc, et al.
Publicado: (2020)

Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer
por: Rajput, Sandeep, et al.
Publicado: (2016)

Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target
por: Ouyang, Zhengxiao, et al.
Publicado: (2019)

Thymidine kinase in breast cancer.
por: Robertson, J. F., et al.
Publicado: (1990)

THYMIDINE TRIPHOSPHATE SYNTHESIS IN TETRAHYMENA : I. Studies on Thymidine Kinase
por: Shoup, G. D., et al.
Publicado: (1966)

INDUCIBILITY OF THYMIDINE KINASE BY THYMIDINE AS A FUNCTION OF INTERPHASE STAGE
por: Hotta, Yasuo, et al.
Publicado: (1965)

Phase I study of palbociclib, a cyclin‐dependent kinase 4/6 inhibitor, in Japanese patients
por: Tamura, Kenji, et al.
Publicado: (2016)

Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients
por: Vlenterie, Myrella, et al.
Publicado: (2016)

Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment
por: Iuliani, Michele, et al.
Publicado: (2022)

Correction: therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target
por: Ouyang, Zhengxiao, et al.
Publicado: (2023)

Palbociclib can overcome mutations in cyclin dependent kinase 6 that break hydrogen bonds between the drug and the protein
por: Hernandez Maganhi, Stella, et al.
Publicado: (2017)

Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy
por: Bonechi, Martina, et al.
Publicado: (2018)

Serum thymidine kinase in acute leukaemia.
por: Hagberg, H., et al.
Publicado: (1984)

Cyclin-Dependent Kinase 4/6 Inhibitor (Palbociclib) Induced Aplastic Anemia in a Patient with Metastatic Breast Cancer
por: Nwabudike, Stanley Madu, et al.
Publicado: (2018)

The Resistance of Cancer Cells to Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, is Mediated by the ABCB1 Transporter
por: Fu, Han, et al.
Publicado: (2022)

Comparison of plasma and tissue thymidine kinase activities.
por: Calvert, R. J., et al.
Publicado: (1989)

Quaternary structure of vaccinia virus thymidine kinase
por: Black, Margaret E., et al.
Publicado: (1990)

ACQUISITION OF CHICK CYTOSOL THYMIDINE KINASE ACTIVITY BY THYMIDINE KINASE-DEFICIENT MOUSE FIBROBLAST CELLS AFTER FUSION WITH CHICK ERYTHROCYTES
por: Kit, Saul, et al.
Publicado: (1974)

3'-Amino thymidine affinity matrix for the purification of herpes simplex virus thymidine kinase.
por: Tung, P. P., et al.
Publicado: (1996)

Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer
por: Larsson, Anna-Maria, et al.
Publicado: (2020)

Vitiligo-like lesions induced by cyclin-dependent kinase 4/6 inhibitor Palbociclib: a case report and literature review
por: Gao, Shan, et al.
Publicado: (2023)

Retrospective natural history of thymidine kinase 2 deficiency
por: Garone, Caterina, et al.
Publicado: (2018)

Coordinate Control of S Phase Onset and Thymidine Kinase Expression
por: Knight, Glenn B., et al.
Publicado: (1989)

Safety and efficacy profile of cyclin‐dependent kinases 4/6 inhibitor palbociclib in cancer therapy: A meta‐analysis of clinical trials
por: Guo, Linghong, et al.
Publicado: (2019)

Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Combination with Ralaniten Analogs for the Treatment of Androgen Receptor–positive Prostate and Breast Cancers
por: Tien, Amy H., et al.
Publicado: (2022)

Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database
por: Bagegni, Nusayba A., et al.
Publicado: (2019)

Cyclin-dependent kinases
por: Malumbres, Marcos
Publicado: (2014)

Therapeutic targeting of transcriptional cyclin-dependent kinases
por: Galbraith, Matthew D., et al.
Publicado: (2018)

Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors
por: Costa Svedman, Fernanda, et al.
Publicado: (2022)

Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma
por: Hsu, Cheng-Lung, et al.
Publicado: (2018)

Evaluation of serum thymidine kinase 1 activity as a biomarker for treatment effectiveness and prediction of relapse in dogs with non‐Hodgkin lymphoma
por: Boyé, Pierre, et al.
Publicado: (2019)

Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer
por: Matikas, A., et al.
Publicado: (2021)

Design of Thymidine Analogues Targeting Thymidilate Kinase of Mycobacterium tuberculosis
por: Owono Owono, Luc Calvin, et al.
Publicado: (2013)

Deoxypyrimidine monophosphate bypass therapy for thymidine kinase 2 deficiency
por: Garone, Caterina, et al.
Publicado: (2014)

Structural and Kinetic Characterization of Thymidine Kinase from Leishmania major
por: Timm, Jennifer, et al.
Publicado: (2015)

Cytotoxicity of trifluridine correlates with the thymidine kinase 1 expression level
por: Kataoka, Yuki, et al.
Publicado: (2019)

Thymidine kinase 1 through the ages: a comprehensive review
por: Bitter, Eliza E., et al.
Publicado: (2020)

Thymidine Kinase(+/−) Mammalian Cell Mutagenicity Assays for Assessment of Nanomaterials
por: Chen, Tao, et al.
Publicado: (2022)

A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis
por: Krishnamurthy, Jairam, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6pnkakp5e2mpvujr28g1r42q8o